The Clock Is Ticking For Nymox Pharma’s European Drug...
Nymox drug, fexapotide, to treat enlarged prostate, is about to have its marketing application decided in Europe within a few...
Research
(If you're unable to access an article, contact us and we'll email you the full article)
10 Reasons Why We Remain Confidently Short Ampio Pharmaceuticals
Although we started shorting Ampio (AMPE) in the high $3s, we continue to hold our short position. We don’t believe...
ClearSign Combustion’s Duplex Technology Is A Commercial Failure; The...
ClearSign Combustion’s Duplex Technology Is A Commercial Failure, The Stock’s Downtrend Will Continue ClearSign’s green energy Duplex technology has been...
Marrone Bio Is Approaching Bankruptcy And Will Have A...
Marrone Bio is broke and approaching bankruptcy with $2M cash burn per month and over $23M in debt principal due...
TransEnterix: What European Da Vinci Surgeons Say About The...
We have reached out to over 100 European surgeons who use the da Vinci surgical robot. The surgeons' opinions on...
PolarityTE: A Comprehensive Look At The Bull Vs Bear...
PolarityTE is a reverse-merger, pre-revenue, pre-clinical tissue regeneration med-tech company with a main product that's patent-pending. PolarityTE’s first product, SkinTE,...
Why Everspin Technologies Is Fading And Will Continue To...
In October 2016, Everspin (MRAM) IPOed at $8 per share and traded there until a Barron's article in May caused...
ShiftPixy Is Just A Struggling Staffing Agency, It Has...
ShiftPixy uses a social networking app to match employers with part-time "shift" employees. ShiftPixy's CEO, Scott Absher, has a checkered...
Ethema Health: A Ground Floor Opportunity In The Rapidly...
At an adjusted book value of $0.066, GRST has limited downside, and is a potential 10x bagger over time. Ethema Health...
Delcath Systems Death Spiral Financing And Luxurious Spending Will...
In the past month, Delcath has risen 1000%+ on promotional hype and no fundamental news. Delcath is engaging in death...
PDL Biopharma Is A Solid Biotech Investment In A...
Specialty pharma company PDL BioPharma has invested a lot in its acquisition of hypertension drug Tekturna, and has hired a...
If Ominto Was A Private Company It Would Be...
If Ominto Was A Private Company, It Would Be Worth A Fraction Of Its Current Price Ominto, an online cash...
Track Record
We have an over 90% success rate
3rd Party Verified:
(click on the stock symbols below to see the reports)
Get Our Latest Reports Delivered To Your Inbox (we will not share your email with anyone)